

REMARKS

Claims 46-51 are pending in the application. Claims 46 and 51 have been cancelled by this amendment. Therefore, claims 47-50 are at issue.

This amendment is in response to a telephone conference with Examiner Sackey on January 27, 2003, and puts the application in a condition for allowance. Nonelected claims 46 and 51 have been cancelled, without prejudice to filing a divisional application directed to the subject matter of these claims. The pendency of dependent claims 47-49 has been changed to depend from claim 50. Claim 50 has been amended as suggested by the examiner.

Pursuant to 37 C.F.R. §1.121, a marked-up version of the changes made to the claims by the present amendment is attached hereto following the signature page of this amendment. The first page of the marked-up version of the changes is captioned "Version With Markings to Show Changes Made."

It is submitted that the claims are in proper form and scope for allowance. Should the examiner wish to discuss the foregoing, the examiner is urged to telephone the undersigned at the indicated number.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By



James J. Napoli
(Registration No. 32,361)
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

Chicago, Illinois
January 27, 2003


Version With Markings to Show Changes Made
(U.S.S.N. 10/077,154)

IN THE CLAIMS:

Claims 46 and 51 have been cancelled without prejudice.

Claims 47-50 have been amended as follows:

47. (Amended) The method of claim [46]
50 wherein the compound has the structure:



48. (Amended) The method of claim [46]
50 wherein the compound is selected from the group consisting of
Methyl (4S,3R)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-([benzylamino]methyl)pyrrolidine carboxylate
Methyl (4S,3R)-3-(aminomethyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methylpyrrolidinecarboxylate
Methyl (3S,4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-([methylsulfonyl]amino)methylpyrrolidinecarboxylate

Methyl (4S,3R)-3-[(acetylamino)methyl]-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methylpyrrolidinecarboxylate

Methyl (4S,3R)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-[(phenylcarbonylamino)methyl]pyrrolidinecarboxylate

Methyl (3S,4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-[(phenylsulfonyl)amino]methylpyrrolidinecarboxylate

Bis{[(4S,3R)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-carboxymethylpyrrolidin-3-yl]methyl}amine

1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethylamine

1-{(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl}ethylamine

N-{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}benzamide

N-{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}benzamide

N-{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}acetamide

N-{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}acetamide


3-(S)-(1-Acetylaminoethyl)-4-(S)-(3-cyclopentyloxy-4-methoxyphenyl)-3-methylpyrrolidine-1-carboxylic acid methyl ester





{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}(phenylsulfonyl)amine



{1-[(3S,4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}(phenylsulfonyl)amine

{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}(methylsulfonyl)amine
{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}(methylsulfonyl)amine, and
Methyl (3S,4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-[(methylamino)ethylpyrrolidine carboxylate.


49. (Amended) The method of claim [46]
50 wherein the compound is the group consisting of:








and



50. (Amended) A method of inhibiting activation of human T-lymphocytes in a mammal comprising administering to said mammal a therapeutically effective amount of a compound having a formula:



wherein R^1 is lower alkyl, bridged alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, a 5- or 6-membered saturated heterocycle, C_{1-4} alkylenearyl, C_{1-4} alkyleneOaryl, C_{1-4} alkyleneheteroaryl, C_{1-4} alkyleneHet, C_{2-4} alkylenearylOaryl, C_{1-4} alkylene bridged alkyl, C_{1-3} alkylenecycloalkyl, substituted or unsubstituted propargyl, substituted or unsubstituted allyl, or halocycloalkyl;

R^2 is hydrogen, methyl, or halo-substituted methyl;

R^3 is selected from the group consisting of $C(=O)OR^7$, $C(=O)R^7$, $C(=NH)NR^8R^9$, $C(=O)NR^8R^9$, lower alkyl, bridged alkyl, cycloalkyl, haloalkyl, halocycloalkyl, C_{1-3} alkylenecycloalkyl, a 5- or 6-membered saturated heterocycle, aryl, heteroaryl, C_{1-3} alkylene $C(=O)R^7$, $C(=O)C(=O)NR^8R^9$, C_{1-4} alkylene OR^7 , C_{1-3} alkylenearyl, SO_2 heteroaryl, Het, aralkyl, alkaryl, heteroaralkyl, heteroalkaryl, C_{1-3} alkylene $C(=O)OR^7$, $C(=O)C_{1-3}$ alkylene $C(=O)OR^7$, C_{1-3} alkyleneheteroaryl, $C(=O)C(=O)OR^7$, $C(=O)C_{1-3}$ alkylene $C(=O)OR^7$, $C(=O)C_{1-3}$ alkylene $NH(C(=O)OR^7)$, $C(=O)C_{1-3}$ alkylene NH_2 , and $NHC(=O)OR^7$;

R^4 is hydrogen, lower alkyl, haloalkyl, cycloalkyl, or aryl;

R^5 is hydrogen, lower alkyl, alkynyl, haloalkyl, cycloalkyl, or aryl;

R^6 and R^{12} , independently, are hydrogen, lower alkyl, aralkyl, SO_2R^{11} , or $C(=O)R^7$;

R^7 is selected from the group consisting of branched or unbranched lower alkyl, heteroaryl, a heterocycle, aralkyl, and aryl, and R^7 can be optionally substituted with one or more of RO^8 , NR^8R^9 , or SR^8 ;

R^8 and R^9 , same or different, are selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, alkaryl, heteroaralkyl, heteroalkaryl, and aralkyl, or R^8 and R^9 can be taken together form a 4-membered to 7-membered ring;

R^{10} is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, $C(=O)alkyl$, $C(=O)cycloalkyl$, $C(=O)aryl$, $C(=O)Oalkyl$, $C(=O)Ocycloalkyl$, $C(=O)aryl$, CH_2OH , $CH_2Oalkyl$, CHO , CN , NO_2 , or SO_2R^{11} ;

R^{11} is alkyl, cycloalkyl, trifluoromethyl, aryl, aralkyl, or NR^8R^9 ;

[salts and solvates thereof] or a salt or solvate thereof.